We partner with companies and teams offering solutions to a broad range of national health security threats.
Pre-exposure Prophylaxis - Influenza
| 1.1 | Anthrax and Smallpox |
| 1.2 | Ebola and Marburg virus |
| 2.1 | Anthrax Antitoxins |
| 2.2 | Botulism Antitoxins |
| 2.3 | Smallpox Antiviral |
| 2.4 | Filovirus Therapeutics |
| 3.1 | Develop products for treatment of MDROs and biothreat pathogens |
| 4.1 | Advanced Development of MCMs to treat radiation injury due to acute exposure to ionizing radiation |
| 4.2 | Blood Products |
| 4.3 | Decorporation Agents |
| 4.4 | Enabling Technologies |
| 5.1 | Pulmonary Agents |
| 5.2 | Opioids |
| 5.3 | Vesicants |
| 5.4 | Blood/Metabolic Agents |
| 5.5 | Nerve Agents and Organophosphorus (OP) Pesticides |
| 5.6 | Novel MCM Delivery Mechanisms |
| 6.1 | Enabling Technologies to Address General Burn & Blast Traumatic Injuries |
| 6.2 | Head & Neck Injuries in Trauma |
| 6.3 | Detection and Management of Internal or External Hemorrhage from Non-Compressible Trauma Wounds |
| 6.4 | Detection and Management of Airway Access Complications in Trauma |
| 6.5 | Non-autologous topical products to prevent or reduce burn wound conversion |
| 7.2 | Biothreat Agent Diagnostics |
| 7.2.1 | Biothreat Agent Diagnostics: Point of Care |
| 7.2.2 | Biothreat Agent Diagnostics: Laboratory |
| 7.2.3 | Molecular Point-Of-Care Diagnostics for Filoviruses |
| 7.3 | Antibiotic Resistance Diagnostics |
| 7.3.1 | Antimicrobial Resistance Testing Direct from Specimen |
| 7.3.2 | Bacterial vs Viral Infections: Point of Care |
| 7.3.3 | Molecular Bacterial Identification and Antimicrobial Susceptibility Testing |
| 7.3.4 | Point of Care Tests for Antibiotic Clinical Trials |
| 7.3.5 | Antimicrobial Resistance Sequencing Solutions |
| 7.3.6 | Novel Phenotypic Antimicrobial Resistance Platforms |
| 7.4 | Radiation Exposure (Biodosimetry) Diagnostics |
| 7.4.1 | Biodosimetry: Self Assessment Tools |
| 7.6 | Influenza Diagnostics |
| 7.6.1 | Influenza Home-use Testing |
| 7.6.2 | Influenza Diagnostics: Emerging Viruses |
| 7.8 | Sequencing System Development |
| 7.8.1 | 'Simplified' Sequencing System Development |
| 8.1 | Advanced development of more effective vaccines |
| 8.2 | Innovative vaccine production enhancements |
| 9.1 | Influenza Antiviral Therapeutics |
| 9.3 | Immunomodulators or therapeutics targeting lung repair |
| 9.6 | Pre-exposure Prophylaxis – Influenza |
BARDA supports advanced research and development of medical countermeasures and is a component of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).
BARDA’s Broad Agency Announcement (BAA) sets forth the advanced research and development Areas of Interest (AOIs) and solicits proposals focusing on these areas in order to protect the United States against public health emergency threats.
